Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Ap...(a In just over a year from incorporatio...),Health

Date:6/29/2009

a, "In just over a year from incorporation in Hong Kong, Pangu BioPharma has demonstrated how well the government, university and industry partnership works. In that short time, with the support of HKUST and funding from the ITC, we have attracted a highly skilled group of scientists, established a well quipped lab at HKUST with the latest technology, and built an IP generating platform at the Pangu BioPharma operations that has already yielded data to support three new patent applications. These inventions are key components of aTyr Pharma's product generating engine, and are proof of the strong support Pangu BioPharma receives from the Hong Kong government and HKUST."

Professor Paul Schimmel of The Scripps Research Institute is a visiting scholar at the Institute of Advanced Science at HKUST and a co-founder of aTyr Pharma as well as Pangu BioPharma. Professor Schimmel was the driver behind building the partnership between aTyr and HKUST. An expert on tRNA synthetases, Paul Schimmel has also been the co-founder or founding director of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, Repligen Corporation, Alkermes, Inc., Momenta Pharmaceuticals and Cubist Pharmaceuticals, which were taken public on the NASDAQ and are well established as companies that develop and market new medicines. "This is an exciting time to launch a biotechnology endeavor in Hong Kong. The government and university system in Hong Kong have a powerful vision to translate their strengths in research into a thriving biotechnology industry that opens the door to the valuable resources of China. aTyr Pharma and Pangu BioPharma are at the forefront of this effort and are pleased to have the ITC and HKUST as partners. We particularly value the contributions of Professors Mingjie Zhang and Nancy Ip of the Biochemistry Department at HKUST, as well as Matthew Yuen of HKUST's Research and Development group," says Professor Schi
'/>"/>

SOURCE aTyr Pharma Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
8. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
9. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
10. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C